Belgian Trial Investigating the LifeStream Stent in Complex TASC C and D Iliac Lesions (BELSTREAM)

Belgian Physician-initiated Trial Investigating the LifeStream Peripheral Stent Graft System for the Treatment of Complex TASC C and D Iliac Lesions

The BELSTREAM Trial investigates the efficacy of the LifeStream Peripheral Stent Graft System in the treatment of iliac stenotic or occlusive lesions (TASC C and D). An expected total of 70 patients will be treated. The lesion is located within the native Iliac arteries. Prior to stenting with the LifeStream Peripheral Stent Graft System, pre-dilatation can be performed according to the physician's discretion. Also post-dilatation can be performed according to the physician's discretion. Patients will be invited for a follow-up visit at 1, 6, 12, 24 ,36 ,48 and 60-month post-procedure. .The primary efficacy endpoint of the study is the primary patency at 12 months. The primary safety endpoint is the freedom of periprocedural Serious Adverse Events (SAEs). Secondary endpoint include primary patency rate at 1 ,6 ,24 ,36 ,48 and 60 month, stent graft occlusion rate at pre-discharge, 1 ,6 ,12 ,24 ,36 ,48 and 60-month follow-up, anke-brachial index (ABI) at 1 ,6 ,12 ,24 ,36 ,48 and 60-month follow-up, amputation rate at 1 ,6 ,12 ,24 ,36 ,48 and 60-month follow-up, technical success and clinical success at 1 ,6 ,12 ,24 ,36 ,48 and 60-month follow-up.

Study Overview

• Status: Completed
• Conditions: Peripheral Arterial Disease
• Intervention / Treatment: Device: LifeStream Peripheral Stent Graft System

Detailed Description

The objective of this clinical investigation is to evaluate, in a controlled setting, the long-term safety and efficacy of the LifeStream Peripheral Stent Graft System in clinical settings post CE-certification when used according to the indications of the IFU with focus on the treatment of complex TASC C and D iliac lesions.

Patients will be selected based on the investigator's assessment, evaluation of the underlying disease and the eligibility criteria. The patient's medical condition should be stable, with no underlying medical condition which would prevent them from performing the required testing or from completing the study. Patients should also be geographically stable, willing and able to cooperate in this clinical study and remain available for long-term follow-up. A patient is considered enrolled in the study after obtaining the patients informed consent, if there is full compliance with the study eligibility criteria and after successful guidewire passage through the study target lesion.

Prior to the index procedure the following tests and clinical data will be collected: informed consent for data collection, demographics, medical history, medication record, physical examination, clinical category of chronic limb ischemia (Rutherford category) and resting ankle-brachial index (ABI).

During the procedure, the vascular access can be achieved to the investigator's standard clinical practice. After successful lesion passage, diagnostic angiography of the lesion area and distal run-off is performed and angiographic measurements (vessel diameter, percentage stenosis and lesion length) are collected. At the physician's discretion, the patient receives at least 1 LifeStream Peripheral Stent Graft System. Pre- and post-dilatation are according to the physician's discretion. No other adjunctive therapies (atherectomy, laser) are allowed. The complete iliac vasculature should be treated in one single session, staged interventions are not allowed. All outflow-limiting lesions must be treated according to the hospital treatment standard.

The regular follow-ups are necessary to monitor the condition of the patient and the stent/procedure. Patients will be invited for a follow-up visit at 1 ,6 ,12 ,24 ,36 ,48 and 60-months after the index procedure. The following data will be collected during these follow-up visit: medication record, physical examination, rutherford categorization, ABI and color flow doppler ultrasound.

• Study Type: Interventional
• Enrollment (Actual): 70
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Belgium
  • Aalst, Belgium, 9300
    • O.L.V. Hospital
  • Antwerp, Belgium, 2060
    • Z.N.A.
  • Bonheiden, Belgium, 2820
    • Imelda Hospital
  • Dendermonde, Belgium, 9200
    • A.Z. Sint-Blasius
  • Genk, Belgium, 3600
    • Z.O.L.
  • Kortrijk, Belgium, 8500
    • AZ Groeninge
  • Tienen, Belgium, 3300
    • R.Z. Heilig Hart

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

General inclusion criteria:

• Corresponding to the CE-mark indications/contra-indications and according to the current medical guidelines for minimally invasive peripheral interventions.
• Patient presenting with a stenotic or occlusive lesion at the iliac arteries suitable for stenting (on indication for primary stenting, based on the discretion of the investigator)
• Patient presenting a score from 2 to 4 following Rutherford classification
• Patient is willing to comply with specified follow-up evaluations at the specified times for the duration of the study
• Patient is >18 years old
• Patient (or their legal representative) understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
• Patient is eligible for treatment with the Lifestream Peripheral Stent Graft System (Bard)

Angiographic inclusion criteria

• The target lesion is either a modified TASC-II class C or D lesion with one of the listed specifications:

  • Type C lesions

    • Bilateral Common Iliac Artery occlusions
    • Bilateral External Iliac Artery stenoses 3-10 cm long not extending into the Common Femoral Artery

  • Type D lesions

    • Unilateral occlusions of both Common Iliac and External Iliac Artery
    • Diffuse disease involving the aorta bifurcation
    • Bilateral occlusions of External Iliac Artery
• The target lesion has angiographic evidence of stenosis or restenosis post percutaneous transluminal angioplasty (PTA) > 50% or occlusion which can be passed with standard guidewire manipulation
• There is angiographic evidence of a patent Common and Deep Femoral Artery

Exclusion criteria:

• PTA is technically not possible (not feasible to access the lesion or a defect with the guidewire or balloon catheter)
• Presence of an aneurysm immediately adjacent to the site of stent graft implantation
• Lesions in or adjacent to essential collaterals(s)
• Lesions in locations subject to external compression
• Heavily calcified lesions resistant to PTA
• Patients with diffuse distal disease resulting in poor stent graft outflow
• Patients with a history of coagulation disorders
• Patients with aspirin allergy or bleeding complications and patients unable or unwilling to tolerate anticoagulant/antiplatelet therapy and/or non-responders to anticoagulant/antiplatelet therapy
• Fresh thrombus formation
• Patients with known hypersensitivity to the stent material (L605) and or polytetrafluroethylene (PTFE)

• The target lesion is either a modified TASC-II class C or D lesion with aortic or common femoral lesion involvement:

  • Type C lesions

    • Unilateral External Iliac Artery stenosis extending into the Common Femoral Artery
    • Unilateral External Iliac Artery occlusion that involves the origins of the Internal Iliac and/or Common Femoral Artery
    • Heavily calcified unilateral External Iliac Artery occlusion with involvement of the Common Femoral Artery

  • Type D lesions

    • Infra-renal aortoiliac occlusion
    • Iliac stenoses in patients with an Abdominal Aortic Aneurysm (AAA) requiring treatment and not amenable to endograft placement or other lesions requiring open aortic or iliac surgery
    • Diffuse multiple stenoses involving the unilateral Common Iliac, External Iliac and Common Femoral Artery
• Previously implanted stent(s) at the same lesion site
• Reference segment diameter is not suitable for the available stent graft design
• Untreatable lesion located at the distal outflow arteries
• Use of alternative therapy (e.g. atherectomy, cutting balloon, drug coated balloon (DCB), laser, radiation therapy) as part of the index procedure
• Patients refusing treatment
• Patients for whom antiplatelet therapy, anticoagulants or thrombolytic drugs are contraindicated
• Perforation at the angioplasty site evidenced by extravasation of contrast medium
• Patients with a history of prior life-threatening contrast medium reaction
• Patients with uncorrected bleeding disorders
• Female patient with child bearing potential not taking adequate contraceptives or currently breastfeeding
• Life expectancy of less than twelve months
• Any planned surgical intervention/procedure within 30 days of the study procedure
• Any patient considered to be hemodynamically unstable at onset of procedure

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: LifeStream Peripheral Stent Graft System; Patients treated with the LifeStream Peripheral Stent Graft System	Device: LifeStream Peripheral Stent Graft System; Patients will be treated with the LifeStream Peripheral Stent Graft System

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Patency Rate Before Completion of the 12-month Follow-up Period.	Target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio greater than 2.5) and with freedom from Target Lesion Revascularization (TLR) before completion of the 12-month follow-up period.	Before the end of the 12 month follow-up window
Number of Periprocedural Serious Adverse Events (SAEs)	Periprocedural SAEs as defined according to the International Organization for Standardization guidelines (ISO) 14155:2011	During the index procedure and within 24 hours post-procedure

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Primary Patency at 1 ,6 ,24 ,36 ,48 and 60- Months Post Procedure	Target lesion without a hemodynamically significant stenosis on duplex ultrasound (>50%, systolic velocity ratio greater than 2.5) and with freedom from Target Lesion Revascularization (TLR)	1 ,6 ,24 ,36 ,48 and 60-months post-procedure
Ankle-Brachial Index (ABI)	ABI at follow-up compared with the baseline ABI	1 ,6 ,12 ,24 ,36 ,48 and 60-month post-procedure
Amputation Rate	Any amputation above the knee	1 ,6 ,12 ,24 ,36 ,48 and 60-months post-procedure
Stent Graft Occlusion Rate	Occlusion of the stent graft system	1 ,6 ,12 ,24 ,36 ,48 and 60-month follow-up
Number of Participants With Technical Success	Ability to achieve final residual angiographic stenosis no greater than 30%	Index procedure
Clinical Success	Rutherford Classification Category (0-6) was assessed according to established clinical criteria for peripheral artery disease. Categories range from 0 (asymptomatic) to 6 (severe tissue loss or gangrene). Classification was determined by the investigator based on symptoms and physical examination. Change from baseline was evaluated at each follow-up visit. Improvement was defined as a decrease of ≥1 Rutherford category compared with baseline.	1 ,6 ,12 ,24 ,36 ,48 and 60-months post-procedure

Collaborators and Investigators

• Sponsor: ID3 Medical
• Investigators: Study Director: Koen Deloose, MD, ID3 Medical

Study record dates

Study Major Dates

• Study Start (Actual): October 31, 2017
• Primary Completion (Actual): October 21, 2020
• Study Completion (Actual): January 15, 2025

Study Registration Dates

• First Submitted: November 17, 2017
• First Submitted That Met QC Criteria: November 17, 2017
• First Posted (Actual): November 22, 2017

Study Record Updates

• Last Update Posted (Actual): March 5, 2026
• Last Update Submitted That Met QC Criteria: February 12, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Atherosclerosis; Arteriosclerosis; Arterial Occlusive Diseases; Peripheral Vascular Diseases; Peripheral Arterial Disease
• Other Study ID Numbers: ID3-20170704

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No